['hiv-1-infection', 'pregnancy related']
['dolutegravir', 'standard of care (efv + 2 nrti backbone)']

        Inclusion Criteria:

          1. Evidence of a personally signed and dated informed consent document indicating that
             the participant has been informed of all pertinent aspects of the study.

          2. Willing and able to comply with scheduled visits, treatment plan, laboratory tests,
             and other study procedures.

          3. Women aged 18 years or older

          4. Pregnant ( ≥28 weeks gestation by best available gestation estimation)

          5. Untreated HIV infection in late pregnancy

        Exclusion Criteria:

          1. Received any antiretroviral drugs in previous 12 months

          2. Ever received integrase inhibitors

          3. Previous documented failure of an NNRTI-containing ART regimen, previous
             EFV-associated toxicity or other history of ARV use that would preclude randomisation
             based on investigator judgement

          4. Serum haemoglobin <8.0 g/dl

          5. eGFR<50 ml/min*

          6. Elevations in serum levels of alanine aminotransferase (ALT) >5 times the upper limit
             of normal (ULN) or ALT >3xULN and bilirubin >2xULN (with >35% direct bilirubin).

          7. History or clinical suspicion of unstable liver disease (as defined by the presence of
             ascites, encephalopathy, coagulopathy, hyperbilirubinaemia, oesophageal or gastric
             varices or persistent jaundice).

          8. Severe pre-eclampsia (e.g. HELLP), or other pregnancy related events such as renal or
             liver abnormalities (e.g. grade 2 or above proteinuria,, total bilirubin, ALT or AST)*
             at the time of enrolment

          9. Paternal objection for infant participation in DTG arm (where disclosure has taken -
             applies to Uganda site only

         10. Medical, psychiatric or obstetric condition that might affect participation in the
             study based on investigator judgement

         11. Receiving any of the following medications (current or within past 2 weeks):
             anti-epileptic drugs, TB therapy, or other drugs known to significantly interact with
             either DTG or EFV
      